Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151418 · ClinicalTrials.gov registry record
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 2,313
- Enrollment target
NCT06151418 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 2,313 participants.
The verdict
NCT06151418 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 2,313 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about- for how long are NHTs taken by men to treat mCSPC. NHTs in this study include study medicines: * abiraterone, * apalutamide, * enzalutamide. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts of the body. Most prostate cancers need male hormones to grow. When cancer cells respond to treatment that lowers male hormones, this is known as castration-sensitive prostate cancer. This is a real-world study, not a clinical trial. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from National Veteran's Affairs (VA) Health Care Network. The study will include patients' information from the database for men who: * were identified to have mCSPC. * started treatment with NHT for mCSPC. * were 18 years of age or older at start of NHT. Men in this study will be taking NHT for treatment of their mCSPC. The study will explain: * how long men take the therapy. * how long it takes to start next therapy. This study will use patient information about medications and treatments from VA data. This study will use information one year before start of NHT until information is available.
Interventions
- DRUG Novel hormonal therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,313 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2024-04-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06151418
The ClinicalTrials.gov registry entry for NCT06151418 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novel hormonal therapy is the first listed.
NCT06151418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06151418 about?
NCT06151418 is a clinical study titled "A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces". The purpose of this study is to learn about- for how long are NHTs taken by men to treat mCSPC. NHTs in this study include study medicines: * abiraterone, * apalutamide, * enzalutamide. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps ma...
What is the current status of trial NCT06151418?
This trial is currently completed. The enrollment target is 2,313 participants. The study started on 2023-11-22. Estimated completion is 2024-04-23.
What interventions are being tested in trial NCT06151418?
The interventions under investigation include: Novel hormonal therapy (DRUG).
Who is sponsoring clinical trial NCT06151418?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.